CureDuchenne Ventures
CureDuchenne Ventures was formed in 2014 after the successful exit from an equity investment in Prosensa (acquired by BioMarin Pharmaceuticals for $680M).
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
){kind=logo}